2006, Number 2
PDF size: 487.59 Kb.
ABSTRACTOver the last few years, three specific eosinophil activating peptides, eotaxin-1, -2 and –3, members of the chemokine family have been identified. These cytokines exert a number of functions on eosinophils including chemotaxis, transendothelial migration and induction of the release of reactive oxygen species. Eosinophils are considered to play an important role in allergic disease by causing tissue damage through the release of toxic proteases, lipid mediators, cytokines and oxygen free radicals. This article reviews the role of eotaxins in asthma and nasal polyps. Discussion focuses on therapeutic guidelines, particularly as it has been shown that CCR3, the major chemokine receptor in eosinophils, serves as a eotaxin receptor.
Stellato C, Brummet EM, Plitt RJ, Shahabuddin S, Baroody MF, Liu CM,et al. Expression of the C-C chemokine receptor CCR3 in human airwayepithelial cells. J Immunol 2001;166:1457-1461. 9.Clemetson KJ, Clemetson JM, Proudfoot AEI, Power CA, Baggiolini M,Wells TNC. Functional expression of CCR1,CCR3,CCR4, and CXCR4chemokine receptors on human platelets. Blood 2000;96:4046-4054.
Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfarlane A, HumbertM, Kay AB. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2,RANTES, monocyte chemoattractant protein-3 (MCP-3), and (MCP-4) andCC chemokine receptor 3 expression in bronchial biopsies from atopic andnonatopic (intrinsic) asthmatic. J Immunol 1999;163:6321-6329.
Ying S, Robinson DS, Meng Q, Barata LT, McEuen AR, Buckley MG, etal. C-C chemokines in allergen-induced late-phase cutaneous responsesin atopic subjects: association of eotaxin with early 6-hour eosinophils, andof eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hourtissue eosinophilia, and relationship to basophils and other C- C chemokines(mono-cyte chemoattractant protein-3 and RANTES). J Immunol1999;163:3976-398436.Teran LM, González L, Valencia-Maqueda E, Negrete-García C. The kineticsof eotaxin-2 release in nasal secretions following nasal allergen challenge: itsinhibition by a topical steroid. J Allergy Clin Immunol 2003;111: A 520.